Skip to content

Source filing unavailable

Q4 2012 · —
Revenue$183.70M+119.9% vs Q4 2011+4.7% vs Q3 2012
Net Income$200.55M+435.2% vs Q4 2011+503.9% vs Q3 2012
EPS Diluted$3.28+315.2% vs Q4 2011+496.4% vs Q3 2012
Gross Profit$156,179,000+102.6%
Operating Incomederived$67,378,000+78.9%
Operating Cash Flowderived$104,345,000+139.0%
Free Cash Flowderived$103,362,000+140.9%
Margins · derived
Gross margin85.0%−7.2 pt vs Q4 2011
Operating margin36.7%−8.4 pt vs Q4 2011
Net margin109.2%+64.3 pt vs Q4 2011

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ4 2012Q4 2011Q4 2010
Revenue$183.70M$83.54M$83.54M
Net Income$200.55M$37.47M$37.47M
EPS Diluted$3.28$0.79$0.79

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR